rick…you make good points re patent panacea…all true….but here’s the thing…why is Denner aggressively pursuing (see San Diego Living reporting on recent filing with USPTO) the issuance of this Lr Patent?…Does Denner’s years of experience (and BOD experience) at the highest levels of healthcare lead him to believe that Amarin , over time, can develop/monetize the Lr formulation opportunity? Or, does Denner already know (or have reason to believe) that a member of big pharma has already checked all the boxes you proffer? My bet is that Denner knows what he is doing in this regard, and has already identified a believer for the Lr formulation opportunity. Shareholder “payday” arrives when the Lr Patent is granted and not at some date in the future when the potential value of the new formulation is demonstrated to Wall Street.
Market Data 
Markets 
AI
